Drug Use & Infections in ViEtnam: Mental Health Intervention for INjecting Drug Users (DRIVEMINDII)
Psychiatric Disorder, Drug Use
About this trial
This is an interventional health services research trial for Psychiatric Disorder focused on measuring psychosis, depression, suicidal risk, drug use, community-based psychiatric intervention
Eligibility Criteria
Inclusion Criteria: Drive Mind II Psychiatric intervention group: Participants of the ANRS 12353/National Institue of Drug Abuse (NIDA) Region of Interest (ROI) DA 041978 DRIVE study (age > 18 years; positive urine test for heroin and/or methamphetamine & skin marks of injection) who either: participated to the DRIVE Mind I cohort were candidate for the DM II control group but were diagnosed at inclusion with a major depressive disorder, psychotic disorder or suicide risk (MINI semi-structured interview) or any other significant psychiatric disorder requiring support and treatment (clinical diagnosis of a psychiatrist); participants recruited in the control group diagnosed at any step of the one-year follow-up with a major depressive disorder, a psychotic disorder or suicide risk (MINI semi-structured interview) or any other significant psychiatric disorder requiring support and treatment (clinical diagnosis of a psychiatrist) at M6 will be proposed to join the psychiatric cohort; Signed informed consent form. Participants eligible for the DM II cohort but refusing the principle of a treatment will nevertheless be included in the psychiatric cohort for follow-up, counselling and support except if the severity of the clinical situation requires immediate hospitalization in the mental health department. Drive Mind II control group Participants of the ANRS 12353/NIDA ROI DA 041978 DRIVE study (age > 18 years; positive urine test for heroin and/or methamphetamine & skin marks of injection): who participated to the DRIVE M30 survey and were screened negative for a potential psychiatric disorder at DRIVE M30 visit (Quick screening tool, QST) and are free of a major depressive disorder, a psychotic disorder or suicide risk (MINI semi-structured interview) or any other significant psychiatric disorder requiring support and treatment (clinical diagnosis of a psychiatrist) at DM II cohort initiation Signed informed consent form. Recruitment in the control group will take place until 200 HIV+ and 200 HIV- are enrolled Exclusion Criteria: Severe psychiatric condition at cohort initiation requiring immediate hospitalization in the mental health department Severe associated diseases requiring specific treatment incompatible with a psychiatric ambulatory follow-up and treatment; Any condition which might, in the investigator's opinion, compromise the safety of the patient by participating in the study including very severe clinical condition; Contraindication for treatment with mirtazapine, sertraline, risperidone, olanzapine, sulpiride, quetiapine, melatonine; Person deprived of freedom by a judicial or administrative decision; Person who plan to move out from Hai Phong in the next 12 months; Person unable to understand the study.
Sites / Locations
- Mental Health DepartmentRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
No Intervention
Psychiatric intervention group
control group free from psychiatric disorder
200 PWID diagnosed with either depression, psychosis or suicidal risk will be proposed to be included in the intervention arm Participants will receive free psychiatric consultation and medication on community-based organization (CBO) sites with full support from CBO members They will receive (together with the control group) linkage to care when needed (HIV, methadone treatment) and harm reduction services.
200 PWID living with HIV and 200 PWID non-infected with HIV, both free of a diagnosis of depression, psychosis or suicidal risk, will be recruited and proposed a one year follow-up. They will receive (together with the intervention group) linkage to care when needed (HIV, methadone treatment) and harm reduction services.